South America Meglitinide Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Expanding Type 2 Diabetes Treatment Pool

South America’s diabetes burden provides a substantial demand base for the South America meglitinide market. The region had 35.4 million adults with diabetes in 2024, and the total is projected to reach 52 million by 2050. Brazil accounted for 17.0 million cases, while Argentina had 4.3 million cases and an age-standardized prevalence of 14%. As 30.4% of regional cases were undiagnosed in 2024, expanded screening can increase the treatment pool. Diabetes-related health expenditure reached USD 81 billion in 2024, underscoring the scale of healthcare demand.^{[1]International Diabetes Federation, “Diabetes Data by Location, South and Central America,” International Diabetes Federation, diabetesatlas.org}

Meal-Time Flexibility and Short-Acting Alternatives

Meglitinides support patients with irregular eating patterns by stimulating insulin release in response to meals. This flexibility benefits shift workers, informal workers, and older adults with variable meal schedules. Nateglinide has a faster onset of action and a lower hypoglycemia risk than repaglinide, supporting its use in selected private specialist settings. Colombia’s 2025 clinical guideline recognized meal-related glucose excursions as a treatment consideration, sustaining a limited role for meglitinides when first-line therapy is unsuitable or insufficient.^{[2]Ministério da Saúde, “Portaria SCTIE/MS Nº 13, de 21 de Fevereiro de 2026,” Ministério da Saúde, gov.br}

Generic Price Accessibility

Generic medicines remain an important affordability mechanism in the South American meglitinide market, as a significant share of volume moves through private pharmacies. EMS S.A. and Glenmark Farmacêutica are among the registered repaglinide manufacturers in Brazil, supporting retail price competition. Lower-priced generic products benefit patients without adequate coverage for newer diabetes medicines. ANVISA’s bioequivalence, quality, and reliance pathways support product registrations while maintaining standards for pharmacies, prescribers, and patients.

Local Registration and Supply-Chain Localization

Local product registration can enable manufacturers to respond more rapidly to demand in the South American meglitinide market. Meglitinide active pharmaceutical ingredients have well-established chemistry and no longer face active patent barriers, making local formulation and regional sourcing feasible for mid-sized generic manufacturers. Brazil’s regulatory framework remains influential as the region’s largest national market, while MERCOSUR-aligned practices can support expansion into neighboring markets. Local supply arrangements can reduce exposure to imported-input delays and currency fluctuations while improving product availability across Brazil and nearby markets.

Non-Incorporation in Brazil’s Sistema Único de Saúde Treatment Protocol

Brazil’s public health system shapes access in the South America meglitinide market, as SUS covers 76% of the population. The February 2026 PCDT DM2 update listed metformin, gliclazide, glibenclamide, dapagliflozin, and insulin analogs but excluded meglitinides. Repaglinide also remained outside RENAME 2024 and lacked support under Santa Catarina’s state dispensing protocol, limiting demand primarily to private retail pharmacies and supplementary insurance channels. The absence of routine public reimbursement increases patient cost exposure and demand volatility, while the 2026 Brazilian Diabetes Society guidance prioritized gliclazide MR among secretagogues.

Therapeutic Substitution by Newer Antidiabetic Classes

Newer antidiabetic therapies represent a key substitution risk for the South America meglitinide market. Argentina’s Resolution 2091/2025 extended mandatory coverage to empagliflozin, canagliflozin, and dapagliflozin for eligible adults with cardiovascular or renal conditions, while Chile and Colombia prioritized SGLT2 inhibitors, GLP-1 receptor agonists, and vildagliptin in treatment pathways. These therapies offer cardiovascular and renal benefits beyond glucose control, strengthening their position against meglitinides. Established alternatives, including metformin, sulfonylureas, DPP-4 inhibitors, and insulin, further narrow the use of meglitinides.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

South America Meglitinide Market Segment Analysis

Repaglinide held 65.12% of the South America meglitinide market in 2025, supported by its long-standing registration history and broad generic base in Brazil. EMS S.A. and Glenmark Farmacêutica market repaglinide products in Brazil through distinct brands and retail channels. The 1 mg and 2 mg formulations have broad availability across pharmacy chains, supporting treatment continuity for patients and prescribers familiar with the molecule. Its established market presence and lower cost in private pharmacies reinforce its position despite guidelines favoring other drug classes for patients with specific comorbidities.

Nateglinide is forecast to be the fastest-growing drug type, expanding at a CAGR of 6.89% from 2026 to 2031. Its faster insulin secretion profile and lower hypoglycemia risk relative to repaglinide support use among some older patients and those with cardiovascular comorbidities. Endocrinologists in private practice may prefer nateglinide for patients taking multiple medications who require a lower interaction burden. Novartis AG’s Starlix brand, licensed from KISSEI Pharmaceutical, maintains visibility in specialist centers and hospital pharmacies, creating a two-track market alongside repaglinide’s broad generic retail presence.

Immediate-release tablets held 55.05% of the South America meglitinide market in 2025. Repaglinide is commonly available in 0.5 mg, 1 mg, and 2 mg tablet strengths, while nateglinide is supplied in 60 mg and 120 mg formulations. These are the standard dosage forms registered for pharmacy dispensing in Brazil and Argentina. Pre-meal administration provides flexibility around meal timing but may increase the pill burden for patients taking multiple medications.

Fixed-strength tablets are forecast to expand at a CAGR of 7.22% from 2026 to 2031, the fastest growth rate among dosage forms. This format can simplify dispensing and reduce dosing errors among patients with lower health literacy. Repaglinide-metformin combinations are available in selected markets and support chronic disease management by reducing the number of separate tablets. ANVISA’s 2026 reliance approach supported the registration of combination products already approved by reference authorities, enabling differentiation beyond standard generic tablets.

Retail pharmacies held 56.55% of the South America meglitinide market in 2025. Brazil’s national pharmacy chains, including Raia Drogasil, Grupo DPSP, and Ultrafarma, provide regular shelf availability for branded and generic products. Argentina’s farmacéuticas and Colombia’s community pharmacies play comparable roles in their respective local markets. Hospital pharmacies remain a secondary channel but have greater relevance for nateglinide in specialist diabetes units, while public hospital protocols in Chile prioritize other diabetes medications.

Online pharmacies are forecast to grow at a CAGR of 6.72% from 2026 to 2031, led by Brazil’s expanding digital pharmacy channel. Prescription-only requirements continue to apply, although meglitinides do not require documentation for specially controlled substances. Brazil’s Law No. 15,357/2026 formalized the framework for online medicine sales, improving clarity for pharmacy operators and supporting electronic prescription fulfillment. Retail pharmacies will remain the primary channel, while online platforms broaden access to lower-cost generic products and facilitate price comparisons.

Geography Analysis

Brazil Meglitinide Market

Brazil held 45.87% of the South America meglitinide market in 2025, making it the region’s largest country market. The country had 17.0 million adults living with diabetes in 2024, and this total is projected to reach 24.0 million by 2050. Private retail pharmacies remain the primary commercial channel because meglitinides were not included in the 2026 SUS DM2 pathway. Brazil’s large population, extensive private pharmacy network, competitive repaglinide generic environment, and substantial diabetes burden sustain its regional leadership.

Argentina Meglitinide Market

Argentina is forecast to grow at a CAGR of 6.45% from 2026 to 2031, the highest rate in the regional forecast. The country had a 14% age-standardized diabetes prevalence and an expanding private insurance and prepaga care environment. Resolution 2091/2025 expanded access to selected SGLT2 inhibitors while leaving meglitinides outside mandatory coverage, directing demand toward private purchases and specialist prescribing. ANMAT’s MERCOSUR-aligned bioequivalence pathway and import-substitution incentives may support generic development, although expanding SGLT2 inhibitor reimbursement remains a market constraint.

South America Meglitinide Market

Colombia and Chile are mid-tier markets with distinct treatment conditions. Colombia had 3.0 million adults living with diabetes in 2024 and an 8.4% prevalence, while Chile had an age-standardized prevalence of 12.2%. Colombia’s clinical guideline favors SGLT2 inhibitors and GLP-1 receptor agonists after metformin, while Chile’s 2026 pathway expanded access to newer therapies in primary care. Peru had a 6.4% diabetes prevalence, and its 2025 guidance did not include meglitinides in the primary treatment sequence, limiting demand largely to lower-volume private prescribing.